CLCS fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Cell Source, Inc. operates as a cell therapy company focused on immunotherapy. Its Veto Cell technology is a next generation immunotherapy technology that enables the selective attenuation of the immune system. The company's Veto Cell platform roadmap consists of two main programs: VETO CAR-T (with and without HSCT) and Veto Cell Organ Transplantation. The company was founded on June 6, 2012 and is headquartered in New York, NY.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
CLCS does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company